Covered recipient · General Payments record
JORDON PROSAPIO
General Payments · PY2020–2024
$1,016.71
- Reported across 27 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $546.50 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $334.72 | 5 |
| IRONSHORE PHARMACEUTICALS INC. | $42.64 | 2 |
| TG THERAPEUTICS, INC. | $31.96 | 1 |
| EISAI INC. | $27.96 | 1 |
| Amgen Inc. | $25.32 | 1 |
| Alexion Pharmaceuticals, Inc. | $21.05 | 1 |
| Supernus Pharmaceuticals, Inc. | $19.74 | 1 |
| ABBVIE INC. | $19.11 | 1 |
| Neurocrine BioSciences, Inc. | $16.59 | 1 |
| Corium, Inc. | $7.41 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.11 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105318476 | CMS |
| Alexion Pharmaceuticals, Inc. | $21.05 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093912658 | CMS |
| Amgen Inc. | $25.32 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111680136 | CMS |
| Corium, LLC | $7.41 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100150095 | CMS |
| Eisai Inc. | $27.96 | 01/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110754910 | CMS |
| IRONSHORE PHARMACEUTICALS INC. | $19.53 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146308403 | CMS |
| IRONSHORE PHARMACEUTICALS INC. | $23.11 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146289390 | CMS |
| Neurocrine Biosciences, Inc. | $16.59 | 03/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150870335 | CMS |
| Supernus Pharmaceuticals, Inc. | $19.74 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147872160 | CMS |
| TG Therapeutics, Inc. | $31.96 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136882702 | CMS |
| UCB, Inc. | $47.70 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143303255 | CMS |
| UCB, Inc. | $125.00 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143303259 | CMS |
| UCB, Inc. | $53.15 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143303264 | CMS |
| UCB, Inc. | $63.68 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143303268 | CMS |
| UCB, Inc. | $45.19 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143298395 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.